Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOTION-4: Anti-thrombotic Therapies in TAVI
NCT06449469Active, not recruiting
- Sponsor
- Rigshospitalet
- Start
- May 2021
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rivaroxaban, edoxaban, dabigatran etexilate oral solution, apixaban and warfarin in thromboembolism (2 arms), sponsored by Rigshospitalet. Primary endpoint: Hypo-attenuated leaflet thickening at 1 year. Started May 2021; status: active, not recruiting.
02
Drugs
rivaroxabanedoxabandabigatran etexilate oral solutionapixabanwarfarin
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT06449469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06449469.